ExploreOutcomeADHD symptom change
Outcome

ADHD symptom change

Also known as: ADHD symptom change and SUD responder status over 16 weeks of treatment (OROS-MPH or placebo + CBT) ADHD symptom change and substance use outcomes over 16 weeks of treatment (OROS-MPH or placebo + CBT) ADHD symptom change over 16 weeks of treatment (OROS-MPH or placebo + CBT) ADHD
9 findings 1 paper 5 related entities View in graph →

Related entities

interventions
conditions
populations
studys

Findings (50)

None
improvement

Greater baseline ADHD severity predicted greater reduction in ADHD symptoms and greater odds of achieving a 50% reduction in substance use, regardless of medication assignment.

Effect: improvement; regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD responder); CI: 95% CI: 1.01 to 1.11 (SUD responder)

Size: regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD re CI: 95% CI: 1.01 to 1.11 (SUD responder)
None
improvement

Greater baseline ADHD severity predicted greater reduction in ADHD symptoms and greater odds of achieving a 50% reduction in substance use, regardless of medication assignment.

Effect: improvement; regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD responder); CI: 95% CI: 1.01 to 1.11 (SUD responder)

Size: regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD re CI: 95% CI: 1.01 to 1.11 (SUD responder)
None
improvement

Greater baseline ADHD severity predicted greater reduction in ADHD symptoms and greater odds of achieving a 50% reduction in substance use, regardless of medication assignment.

Effect: improvement; regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD responder); CI: 95% CI: 1.01 to 1.11 (SUD responder)

Size: regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD re CI: 95% CI: 1.01 to 1.11 (SUD responder)
None
improvement

Greater baseline ADHD severity predicted greater reduction in ADHD symptoms and greater odds of achieving a 50% reduction in substance use, regardless of medication assignment.

Effect: improvement; regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD responder); CI: 95% CI: 1.01 to 1.11 (SUD responder)

Size: regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD re CI: 95% CI: 1.01 to 1.11 (SUD responder)
None
improvement

Greater baseline ADHD severity predicted greater reduction in ADHD symptoms and greater odds of achieving a 50% reduction in substance use, regardless of medication assignment.

Effect: improvement; regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD responder); CI: 95% CI: 1.01 to 1.11 (SUD responder)

Size: regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD re CI: 95% CI: 1.01 to 1.11 (SUD responder)
None
improvement

Greater baseline ADHD severity predicted greater reduction in ADHD symptoms and greater odds of achieving a 50% reduction in substance use, regardless of medication assignment.

Effect: improvement; regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD responder); CI: 95% CI: 1.01 to 1.11 (SUD responder)

Size: regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD re CI: 95% CI: 1.01 to 1.11 (SUD responder)
None
improvement

Greater baseline ADHD severity predicted greater reduction in ADHD symptoms and greater odds of achieving a 50% reduction in substance use, regardless of medication assignment.

Effect: improvement; regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD responder); CI: 95% CI: 1.01 to 1.11 (SUD responder)

Size: regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD re CI: 95% CI: 1.01 to 1.11 (SUD responder)
None
improvement

Greater baseline ADHD severity predicted greater reduction in ADHD symptoms and greater odds of achieving a 50% reduction in substance use, regardless of medication assignment.

Effect: improvement; regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD responder); CI: 95% CI: 1.01 to 1.11 (SUD responder)

Size: regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD re CI: 95% CI: 1.01 to 1.11 (SUD responder)
None
improvement

Greater baseline ADHD severity predicted greater reduction in ADHD symptoms and greater odds of achieving a 50% reduction in substance use, regardless of medication assignment.

Effect: improvement; regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD responder); CI: 95% CI: 1.01 to 1.11 (SUD responder)

Size: regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD re CI: 95% CI: 1.01 to 1.11 (SUD responder)
None
improvement

Greater baseline ADHD severity predicted greater reduction in ADHD symptoms and greater odds of achieving a 50% reduction in substance use, regardless of medication assignment.

Effect: improvement; regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD responder); CI: 95% CI: 1.01 to 1.11 (SUD responder)

Size: regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD re CI: 95% CI: 1.01 to 1.11 (SUD responder)
None
improvement

Greater baseline ADHD severity predicted greater reduction in ADHD symptoms and greater odds of achieving a 50% reduction in substance use, regardless of medication assignment.

Effect: improvement; regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD responder); CI: 95% CI: 1.01 to 1.11 (SUD responder)

Size: regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD re CI: 95% CI: 1.01 to 1.11 (SUD responder)
None
improvement

Greater baseline ADHD severity predicted greater reduction in ADHD symptoms and greater odds of achieving a 50% reduction in substance use, regardless of medication assignment.

Effect: improvement; regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD responder); CI: 95% CI: 1.01 to 1.11 (SUD responder)

Size: regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD re CI: 95% CI: 1.01 to 1.11 (SUD responder)
None
improvement

Greater baseline ADHD severity predicted greater reduction in ADHD symptoms and greater odds of achieving a 50% reduction in substance use, regardless of medication assignment.

Effect: improvement; regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD responder); CI: 95% CI: 1.01 to 1.11 (SUD responder)

Size: regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD re CI: 95% CI: 1.01 to 1.11 (SUD responder)
None
improvement

Greater baseline ADHD severity predicted greater reduction in ADHD symptoms and greater odds of achieving a 50% reduction in substance use, regardless of medication assignment.

Effect: improvement; regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD responder); CI: 95% CI: 1.01 to 1.11 (SUD responder)

Size: regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD re CI: 95% CI: 1.01 to 1.11 (SUD responder)
None
improvement

Greater baseline ADHD severity predicted greater reduction in ADHD symptoms and greater odds of achieving a 50% reduction in substance use, regardless of medication assignment.

Effect: improvement; regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD responder); CI: 95% CI: 1.01 to 1.11 (SUD responder)

Size: regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD re CI: 95% CI: 1.01 to 1.11 (SUD responder)
None
improvement

Greater baseline ADHD severity predicted greater reduction in ADHD symptoms and greater odds of achieving a 50% reduction in substance use, regardless of medication assignment.

Effect: improvement; regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD responder); CI: 95% CI: 1.01 to 1.11 (SUD responder)

Size: regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD re CI: 95% CI: 1.01 to 1.11 (SUD responder)
None
improvement

Greater baseline ADHD severity predicted greater reduction in ADHD symptoms and greater odds of achieving a 50% reduction in substance use, regardless of medication assignment.

Effect: improvement; regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD responder); CI: 95% CI: 1.01 to 1.11 (SUD responder)

Size: regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD re CI: 95% CI: 1.01 to 1.11 (SUD responder)
None
improvement

Greater baseline ADHD severity predicted greater reduction in ADHD symptoms and greater odds of achieving a 50% reduction in substance use, regardless of medication assignment.

Effect: improvement; regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD responder); CI: 95% CI: 1.01 to 1.11 (SUD responder)

Size: regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD re CI: 95% CI: 1.01 to 1.11 (SUD responder)
None
improvement

Greater baseline ADHD severity predicted greater reduction in ADHD symptoms and greater odds of achieving a 50% reduction in substance use, regardless of medication assignment.

Effect: improvement; regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD responder); CI: 95% CI: 1.01 to 1.11 (SUD responder)

Size: regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD re CI: 95% CI: 1.01 to 1.11 (SUD responder)
None
improvement

Greater baseline ADHD severity predicted greater reduction in ADHD symptoms and greater odds of achieving a 50% reduction in substance use, regardless of medication assignment.

Effect: improvement; regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD responder); CI: 95% CI: 1.01 to 1.11 (SUD responder)

Size: regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD re CI: 95% CI: 1.01 to 1.11 (SUD responder)
None
improvement

Greater baseline ADHD severity predicted greater reduction in ADHD symptoms and greater odds of achieving a 50% reduction in substance use, regardless of medication assignment.

Effect: improvement; regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD responder); CI: 95% CI: 1.01 to 1.11 (SUD responder)

Size: regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD re CI: 95% CI: 1.01 to 1.11 (SUD responder)
None
improvement

Greater baseline ADHD severity predicted greater reduction in ADHD symptoms and greater odds of achieving a 50% reduction in substance use, regardless of medication assignment.

Effect: improvement; regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD responder); CI: 95% CI: 1.01 to 1.11 (SUD responder)

Size: regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD re CI: 95% CI: 1.01 to 1.11 (SUD responder)
None
improvement

Greater baseline ADHD severity predicted greater reduction in ADHD symptoms and greater odds of achieving a 50% reduction in substance use, regardless of medication assignment.

Effect: improvement; regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD responder); CI: 95% CI: 1.01 to 1.11 (SUD responder)

Size: regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD re CI: 95% CI: 1.01 to 1.11 (SUD responder)
None
improvement

Greater baseline ADHD severity predicted greater reduction in ADHD symptoms and greater odds of achieving a 50% reduction in substance use, regardless of medication assignment.

Effect: improvement; regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD responder); CI: 95% CI: 1.01 to 1.11 (SUD responder)

Size: regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD re CI: 95% CI: 1.01 to 1.11 (SUD responder)
None
improvement

Greater baseline ADHD severity predicted greater reduction in ADHD symptoms and greater odds of achieving a 50% reduction in substance use, regardless of medication assignment.

Effect: improvement; regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD responder); CI: 95% CI: 1.01 to 1.11 (SUD responder)

Size: regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD re CI: 95% CI: 1.01 to 1.11 (SUD responder)
None
improvement

Greater baseline ADHD severity predicted greater reduction in ADHD symptoms and greater odds of achieving a 50% reduction in substance use, regardless of medication assignment.

Effect: improvement; regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD responder); CI: 95% CI: 1.01 to 1.11 (SUD responder)

Size: regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD re CI: 95% CI: 1.01 to 1.11 (SUD responder)
None
improvement

Greater baseline ADHD severity predicted greater reduction in ADHD symptoms and greater odds of achieving a 50% reduction in substance use, regardless of medication assignment.

Effect: improvement; regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD responder); CI: 95% CI: 1.01 to 1.11 (SUD responder)

Size: regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD re CI: 95% CI: 1.01 to 1.11 (SUD responder)
None
decline

Greater baseline substance use severity predicted less improvement in ADHD symptoms and fewer negative urine drug screens during 16 weeks of treatment, regardless of medication assignment.

Effect: decline; regression coefficient = -0.35 (ADHD change); regression coefficient = -0.08 (negative urine samples)

Size: regression coefficient = -0.35 (ADHD change); regression coe
None
decline

Greater baseline substance use severity predicted less improvement in ADHD symptoms and fewer negative urine drug screens during 16 weeks of treatment, regardless of medication assignment.

Effect: decline; regression coefficient = -0.35 (ADHD change); regression coefficient = -0.08 (negative urine samples)

Size: regression coefficient = -0.35 (ADHD change); regression coe
None
decline

Greater baseline substance use severity predicted less improvement in ADHD symptoms and fewer negative urine drug screens during 16 weeks of treatment, regardless of medication assignment.

Effect: decline; regression coefficient = -0.35 (ADHD change); regression coefficient = -0.08 (negative urine samples)

Size: regression coefficient = -0.35 (ADHD change); regression coe
None
decline

Greater baseline substance use severity predicted less improvement in ADHD symptoms and fewer negative urine drug screens during 16 weeks of treatment, regardless of medication assignment.

Effect: decline; regression coefficient = -0.35 (ADHD change); regression coefficient = -0.08 (negative urine samples)

Size: regression coefficient = -0.35 (ADHD change); regression coe
None
decline

Greater baseline substance use severity predicted less improvement in ADHD symptoms and fewer negative urine drug screens during 16 weeks of treatment, regardless of medication assignment.

Effect: decline; regression coefficient = -0.35 (ADHD change); regression coefficient = -0.08 (negative urine samples)

Size: regression coefficient = -0.35 (ADHD change); regression coe
None
decline

Greater baseline substance use severity predicted less improvement in ADHD symptoms and fewer negative urine drug screens during 16 weeks of treatment, regardless of medication assignment.

Effect: decline; regression coefficient = -0.35 (ADHD change); regression coefficient = -0.08 (negative urine samples)

Size: regression coefficient = -0.35 (ADHD change); regression coe
None
decline

Greater baseline substance use severity predicted less improvement in ADHD symptoms and fewer negative urine drug screens during 16 weeks of treatment, regardless of medication assignment.

Effect: decline; regression coefficient = -0.35 (ADHD change); regression coefficient = -0.08 (negative urine samples)

Size: regression coefficient = -0.35 (ADHD change); regression coe
None
decline

Greater baseline substance use severity predicted less improvement in ADHD symptoms and fewer negative urine drug screens during 16 weeks of treatment, regardless of medication assignment.

Effect: decline; regression coefficient = -0.35 (ADHD change); regression coefficient = -0.08 (negative urine samples)

Size: regression coefficient = -0.35 (ADHD change); regression coe
None
decline

Greater baseline substance use severity predicted less improvement in ADHD symptoms and fewer negative urine drug screens during 16 weeks of treatment, regardless of medication assignment.

Effect: decline; regression coefficient = -0.35 (ADHD change); regression coefficient = -0.08 (negative urine samples)

Size: regression coefficient = -0.35 (ADHD change); regression coe
None
decline

Greater baseline substance use severity predicted less improvement in ADHD symptoms and fewer negative urine drug screens during 16 weeks of treatment, regardless of medication assignment.

Effect: decline; regression coefficient = -0.35 (ADHD change); regression coefficient = -0.08 (negative urine samples)

Size: regression coefficient = -0.35 (ADHD change); regression coe
None
decline

Greater baseline substance use severity predicted less improvement in ADHD symptoms and fewer negative urine drug screens during 16 weeks of treatment, regardless of medication assignment.

Effect: decline; regression coefficient = -0.35 (ADHD change); regression coefficient = -0.08 (negative urine samples)

Size: regression coefficient = -0.35 (ADHD change); regression coe
None
decline

Greater baseline substance use severity predicted less improvement in ADHD symptoms and fewer negative urine drug screens during 16 weeks of treatment, regardless of medication assignment.

Effect: decline; regression coefficient = -0.35 (ADHD change); regression coefficient = -0.08 (negative urine samples)

Size: regression coefficient = -0.35 (ADHD change); regression coe
None
decline

Greater baseline substance use severity predicted less improvement in ADHD symptoms and fewer negative urine drug screens during 16 weeks of treatment, regardless of medication assignment.

Effect: decline; regression coefficient = -0.35 (ADHD change); regression coefficient = -0.08 (negative urine samples)

Size: regression coefficient = -0.35 (ADHD change); regression coe
None
decline

Greater baseline substance use severity predicted less improvement in ADHD symptoms and fewer negative urine drug screens during 16 weeks of treatment, regardless of medication assignment.

Effect: decline; regression coefficient = -0.35 (ADHD change); regression coefficient = -0.08 (negative urine samples)

Size: regression coefficient = -0.35 (ADHD change); regression coe
None
decline

Greater baseline substance use severity predicted less improvement in ADHD symptoms and fewer negative urine drug screens during 16 weeks of treatment, regardless of medication assignment.

Effect: decline; regression coefficient = -0.35 (ADHD change); regression coefficient = -0.08 (negative urine samples)

Size: regression coefficient = -0.35 (ADHD change); regression coe
None
decline

Greater baseline substance use severity predicted less improvement in ADHD symptoms and fewer negative urine drug screens during 16 weeks of treatment, regardless of medication assignment.

Effect: decline; regression coefficient = -0.35 (ADHD change); regression coefficient = -0.08 (negative urine samples)

Size: regression coefficient = -0.35 (ADHD change); regression coe
None
decline

Greater baseline substance use severity predicted less improvement in ADHD symptoms and fewer negative urine drug screens during 16 weeks of treatment, regardless of medication assignment.

Effect: decline; regression coefficient = -0.35 (ADHD change); regression coefficient = -0.08 (negative urine samples)

Size: regression coefficient = -0.35 (ADHD change); regression coe
None
decline

Greater baseline substance use severity predicted less improvement in ADHD symptoms and fewer negative urine drug screens during 16 weeks of treatment, regardless of medication assignment.

Effect: decline; regression coefficient = -0.35 (ADHD change); regression coefficient = -0.08 (negative urine samples)

Size: regression coefficient = -0.35 (ADHD change); regression coe
None
decline

Greater baseline substance use severity predicted less improvement in ADHD symptoms and fewer negative urine drug screens during 16 weeks of treatment, regardless of medication assignment.

Effect: decline; regression coefficient = -0.35 (ADHD change); regression coefficient = -0.08 (negative urine samples)

Size: regression coefficient = -0.35 (ADHD change); regression coe
None
decline

Greater baseline substance use severity predicted less improvement in ADHD symptoms and fewer negative urine drug screens during 16 weeks of treatment, regardless of medication assignment.

Effect: decline; regression coefficient = -0.35 (ADHD change); regression coefficient = -0.08 (negative urine samples)

Size: regression coefficient = -0.35 (ADHD change); regression coe
None
decline

Greater baseline substance use severity predicted less improvement in ADHD symptoms and fewer negative urine drug screens during 16 weeks of treatment, regardless of medication assignment.

Effect: decline; regression coefficient = -0.35 (ADHD change); regression coefficient = -0.08 (negative urine samples)

Size: regression coefficient = -0.35 (ADHD change); regression coe
None
decline

Greater baseline substance use severity predicted less improvement in ADHD symptoms and fewer negative urine drug screens during 16 weeks of treatment, regardless of medication assignment.

Effect: decline; regression coefficient = -0.35 (ADHD change); regression coefficient = -0.08 (negative urine samples)

Size: regression coefficient = -0.35 (ADHD change); regression coe
None
decline

Greater baseline substance use severity predicted less improvement in ADHD symptoms and fewer negative urine drug screens during 16 weeks of treatment, regardless of medication assignment.

Effect: decline; regression coefficient = -0.35 (ADHD change); regression coefficient = -0.08 (negative urine samples)

Size: regression coefficient = -0.35 (ADHD change); regression coe

Papers (1)